LONDON (Alliance News) - Biopharmaceutical company Motif Bio PLC on Tuesday said the clinical trial supplies for its iclaprim antibiotic product have been manufactured.
The completion of this work will leave the company on target to complete its two phase III trials of the drug, design to treat skin infections, by the second half of 2017.
"This is a major milestone for Motif given the complexity and costs usually associated with the manufacture of clinical trial supplies in sufficient quantity for large Phase III trials," said Chief Executive Graham Lumsden.
Motif Bio shares were up 2.5% to 40.5 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
